Хірургічне втручання у пацієнтів, які проходять антитромбоцитарну терапію 5 страница

284. Ellis SG, da Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, Spaulding C,­Nobuyoshi M, Erbel R, Vassanelli Cet al. Randomized comparison of rescue angioplasty­with conservative management of patients with early failure of thrombolysis­for acute anterior myocardial infarction. Circulation 1994;90(5):2280–2284

285. Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE,­Disesa VJ, Hiratzka LF, Hutter AM Jr., Jessen ME, Keeley EC, Lahey SJ, Lange RA,­London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM,­Trost JC, Winniford MD. 2011 ACCF/AHA Guideline for Coronary Artery­Bypass Graft Surgery: a report of the American College of Cardiology Foundation/­American Heart Association Task Force on Practice Guidelines. Circulation­2011;124(23):e652–e735

286. Weiss ES, Chang DD, Joyce DL, Nwakanma LU, Yuh DD. Optimal timing of coronary­artery bypass after acute myocardial infarction: a review of California discharge­data. J Thorac Cardiovasc Surg 2008;135(3):503–11, 511 e1–e3

287. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V,­Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY,­Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH,­Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A

ESC Guidelines for the diagnosis and treatment of acute and chronic heart­failure 2012: The Task Force for the Diagnosis and Treatment of Acute and­Chronic Heart Failure 2012 of the European Society of Cardiology. Developed­in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart­J 2012;33(14):1787–1847

288. Velazquez EJ, Williams JB, Yow E, Shaw LK, Lee KL, Phillips HR, O’Connor CM,­Smith PK, Jones RH. Long-term survival of patients with ischemic cardiomyopathy­treated by coronary artery bypass grafting vs. medical therapy. Ann Thorac Surg­2012;93(2):523–530

289. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, Drozdz J,­Farsky PS, Feldman AM, Doenst T, Michler RE, Berman DS, Nicolau JC, Pellikka PA,­Wrobel K, Alotti N, Asch FM, Favaloro LE, She L, Velazquez EJ, Jones RH, Panza JA,­Investigators ST. Myocardial viability and survival in ischemic left ventricular dysfunction N Engl J Med 2011;364(17):1617–1625

290. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD,­Hachamovitch R. Identification of therapeutic benefit from revascularization in­patients with left ventricular systolic dysfunction: inducible ischemia vs. hibernating­myocardium. Circ Cardiovasc Imaging 2013;6(3):363–372

291. Di Donato M, Castelvecchio S, Menicanti L. End-systolic volume following surgical­ventricular reconstruction impacts survival in patients with ischaemic dilated cardiomyopathy Eur J Heart Fail 2010;12(4):375–381

292. Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O’Connor CM, Hill JA,­Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KL. Coronary­bypass surgery with or without surgical ventricular reconstruction. N Engl J Med­2009;360(17):1705–1717

293. Oh JK, Velazquez EJ, Menicanti L, Pohost GM, Bonow RO, Lin G, Hellkamp AS,­Ferrazzi P, Wos S, Rao V, Berman D, Bochenek A, Cherniavsky A, Rogowski J,­Rouleau JL, Lee KL, Investigators S. Influence of baseline left ventricular function­on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic­cardiomyopathy. Eur Heart J 2013;34(1):39–47

294. Michler RE, Rouleau JL, Al-Khalidi HR, Bonow RO, Pellikka PA, Pohost GM,­Holly TA, Oh JK, Dagenais F, Milano C, Wrobel K, Pirk J, Ali IS, Jones RH,­Velazquez EJ, Lee KL, DiDonato M. Insights from the STICH trial: change in left ventricular­size after coronary artery bypass grafting with and without surgical ventricular­reconstruction. J Thorac Cardiovasc Surg 2013;146(5):1139–1145 e6

295. Dor V, Civaia F, Alexandrescu C, Sabatier M, Montiglio F. Favorable effects of left­ventricular reconstruction in patients excluded from the Surgical Treatments for­Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg 2011;141(4):905–­916, 916 e1–e4

296. Lindholm MG, Kober L, Boesgaard S, Torp-Pedersen C, Aldershvile J, Trandolapril­Cardiac Evaluation study g. Cardiogenic shock complicating acute myocardial infarction;­prognostic impact of early and late shock development. Eur Heart J­2003;24(3):258–265

297. Katz JN, Stebbins AL, Alexander JH, Reynolds HR, Pieper KS, RuzylloW,Werdan K,­Geppert A, Dzavik V, Van de Werf F, Hochman JS, Investigators T. Predictors of­30-day mortality in patients with refractory cardiogenic shock following acutemyocardial­infarction despite a patent infarct artery. Am Heart J 2009;158(4):680–687

298. Zeymer U, Vogt A, Zahn R,Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J,­Neuhaus KL, Arbeitsgemeinschaft Leitende Kardiologische K. Predictors of­in-hospital mortality in 1333 patients with acute myocardial infarction complicated­by cardiogenic shock treated with primary percutaneous coronary intervention­(PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische­Krankenhausarzte (ALKK). Eur Heart J 2004;25(4):322–328

299. Dzavik V, Sleeper LA, Cocke TP, Moscucci M, Saucedo J, Hosat S, Jiang X, Slater J,­LeJemtel T, Hochman JS, Investigators S. Early revascularization is associated with­improved survival in elderly patients with acute myocardial infarction complicated­by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003;­24(9):828–837

300. Kantrowitz A, Tjonneland S, Freed PS, Phillips SJ, Butner AN, Sherman JL Jr. Initial­clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA­1968;203(2):113–118

301. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G,­Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J,­Bohm M, Ebelt H, Schneider S, Schuler G,Werdan K, Investigators I-SIT. Intraaortic­balloon support for myocardial infarction with cardiogenic shock. N Engl J Med­2012;367(14):1287–1296

302. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, deWaha A,­Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R,­Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G. Intra-aortic­balloon counterpulsation in acute myocardial infarction complicated by cardiogenic­shock (IABP-SHOCK II): final 12 month results of a randomised, open-label­trial. Lancet 2013;382(9905):1638–1645

303. Burkhoff D, Cohen H, Brunckhorst C, O’NeillWW, TandemHeart Investigators G A randomized multicenter clinical study to evaluate the safety and efficacy of the­TandemHeart percutaneous ventricular assist device vs. conventional therapy­with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J­2006;152(3):469 e1–e8

304. Kar B, Basra SS, Shah NR, Loyalka P. Percutaneous circulatory support in cardiogenic­shock: interventional bridge to recovery. Circulation 2012;125(14):­1809–1817

305. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G Randomized comparison of intra-aortic balloon support with a percutaneous left­ventricular assist device in patients with revascularized acute myocardial infarction­complicated by cardiogenic shock. Eur Heart J 2005;26(13):1276–1283

306. Seyfarth M, Sibbing D, Bauer I, Frohlich G, Bott-Flugel L, Byrne R, Dirschinger J,­Kastrati A, Schomig A. A randomized clinical trial to evaluate the safety and efficacy­of a percutaneous left ventricular assist device vs. intra-aortic balloon pumping for­treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol­2008;52(19):1584–1588

307. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT,­Serruys PW. Percutaneous left ventricular assist devices vs. intra-aortic balloon­pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled­trials. Eur Heart J 2009;30(17):2102–2108

308. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Baldwin JT,­Young JB. The Fourth INTERMACS Annual Report: 4,000 implants and counting J Heart Lung Transplant 2012;31(2):117–126

309. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Timothy­Baldwin J, Young JB. Fifth INTERMACS annual report: risk factor analysis from­more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant­2013;32(2):141–156

310. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson L, Miller M, Young JB. Longterm­mechanical circulatory support (destination therapy): on track to compete­with heart transplantation? J Thorac Cardiovasc Surg 2012;144(3):584–603; discussion­597–598

311. Cohn JN, Guiha NH, Broder MI, Limas CJ. Right ventricular infarction. Clinical and­hemodynamic features. Am J Cardiol 1974;33(2):209–214

312. Dell’Italia LJ, Starling MR, Crawford MH, Boros BL, Chaudhuri TK, O’Rourke RA Right ventricular infarction: identification by hemodynamic measurements­before after volume loading correlation with noninvasive techniques. J Am Coll­Cardiol 1984;4(5):931–939

313. Goldstein JA. Pathophysiology and management of right heart ischemia. J Am Coll­Cardiol 2002;40(5):841–853

314. Goldstein JA, Barzilai B, Rosamond TL, Eisenberg PR, Jaffe AS. Determinants of­hemodynamic compromise with severe right ventricular infarction. Circulation­1990;82(2):359–368

315. Lorell B, Leinbach RC, Pohost GM, Gold HK, Dinsmore RE, Hutter AM Jr.,­Pastore JO, DesanctisRW. Right ventricular infarction. Clinical diagnosis and differentiation­from cardiac tamponade and pericardial constriction. Am J Cardiol 1979;­43(3):465–471

316. Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R,­Boland J, Modur S, Forman R, Hochman JS. Cardiogenic shock caused by right ventricular­infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003;41(8):­1273–1279

317. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E,­White HD, Lim J, LeJemtel T. Cardiogenic shock complicating acute myocardial­infarction:etiologies, management and outcome: a report from the SHOCK Trial­Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic­shocK? J Am Coll Cardiol 2000;36(3 Suppl A):1063–1070

318. Brodie BR, Stuckey TD, Hansen C, Bradshaw BH, Downey WE, Pulsipher MW Comparison of late survival in patients with cardiogenic shock due to right ventricular­infarction vs. left ventricular pump failure following primary percutaneous­coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol­2007;99(4):431–435

319. Zeymer U, Neuhaus KL,Wegscheider K, Tebbe U, Molhoek P, Schroder R. Effects­of thrombolytic therapy in acute inferior myocardial infarction with or without­right ventricular involvement. HIT-4 Trial Group. Hirudin for Improvement of­Thrombolysis. J Am Coll Cardiol 1998;32(4):876–881

320. The effects of tissue plasminogen activator, streptokinase, or both on­coronary-artery patency, ventricular function, and survival after acute myocardial­infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993;329(22):­1615–1622

321. Kinn JW, O’Neill WW, Benzuly KH, Jones DE, Grines CL. Primary angioplasty­reduces risk of myocardial rupture compared to thrombolysis for acute myocardial­infarction. Cathet Cardiovasc Diagn 1997;42(2):151–157

322. Moreno R, Lopez-Sendon J, Garcia E, Perez de Isla L, Lopez de Sa E, Ortega A,­Moreno M, Rubio R, Soriano J, Abeytua M, Garcia-Fernandez MA. Primary angioplasty­reduces the risk of left ventricular free wall rupture compared with thrombolysis­in patients with acute myocardial infarction. J Am Coll Cardiol 2002;39(4):­598–603

323. Menon V,Webb JG, Hillis LD, Sleeper LA, Abboud R, DzavikV, Slater JN, Forman R,­Monrad ES, Talley JD, Hochman JS. Outcome and profile of ventricular septal­rupture with cardiogenic shock after myocardial infarction: a report from the­SHOCKTrial Registry. SHould we emergently revascularize Occluded Coronaries­in cardiogenic shocK? J Am Coll Cardiol 2000;36(3 Suppl A):1110–1116

324. Thiele H, Kaulfersch C, Daehnert I, Schoenauer M, Eitel I, Borger M, Schuler G. Immediate­primary transcatheter closure of postinfarction ventricular septal defects Eur Heart J 2009;30(1):81–88

325. Zhu XY, Qin YW, Han YL, Zhang DZ, Wang P, Liu YF, Xu YW, Jing QM, Xu K,­Gersh BJ, Wang XZ. Long-term efficacy of transcatheter closure of ventricular­septal defect in combination with percutaneous coronary intervention in patients­with ventricular septal defect complicating acute myocardial infarction: a multicentre­study. EuroIntervention 2013;8(11):1270–1276

326. Assenza GE, McElhinney DB, Valente AM, Pearson DD, Volpe M, Martucci G,­Landzberg MJ, Lock JE. Transcatheter closure of post-myocardial infarction ventricular­septal rupture. Circ Cardiovasc Interv 2013;6(1):59–67

327. Slater J, Brown RJ, Antonelli TA, Menon V, Boland J, Col J, Dzavik V, Greenberg M,­Menegus M, Connery C, Hochman JS. Cardiogenic shock due to cardiac free-wall­rupture or tamponade after acute myocardial infarction: a report from theSHOCK­Trial Registry. Should weemergently revascularize occluded coronaries for cardiogenic­shock? J Am Coll Cardiol 2000;36(3 Suppl A):1117–1122

328. Lopez-Sendon J, Gonzalez A, Lopez de Sa E, Coma-Canella I, Roldan I,­Dominguez F, Maqueda I, Martin Jadraque L. Diagnosis of subacute ventricular­wall rupture after acute myocardial infarction: sensitivity and specificity of clinical,­hemodynamic and echocardiographic criteria. J Am Coll Cardiol 1992;19(6):­1145–1153

329. Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Hasdai D,­Holmes DR, Bates ER, Topol EJ, Califf RM, Ohman EM. Lack of progress in cardiogenic­shock: lessons from the GUSTO trials. Eur Heart J 2000;21(23):1928–1936

330. Chevalier P, Burri H, Fahrat F, Cucherat M, Jegaden O, Obadia JF, Kirkorian G,­Touboul P. Perioperativeoutcome and long-term survival of surgery for acute postinfarction­mitral regurgitation. Eur J Cardiothorac Surg 2004;26(2):330–335

331. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J,­White HD, Investigators S. Early revascularization and long-termsurvival in cardiogenic­shock complicating acute myocardial infarction. JAMA 2006;295(21):­2511–2515

332. Sjauw KD, Engstrom AE, VisMM,van der Schaaf RJ, Baan J Jr., KochKT, de Winter RJ,­Piek JJ, Tijssen JG, Henriques JP. A systematic review and meta-analysis of­intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should­we change the guidelines? Eur Heart J 2009;30(4):459–468

333. Buerke M, Prondzinsky R, Lemm H, Dietz S, Buerke U, Ebelt H, Bushnaq H,­Silber RE, Werdan K. Intra-aortic balloon counterpulsation in the treatment of­infarction-related cardiogenic shock:review of the current evidence. Artif Organs­2012;36(6):505–511

334. Frye RL, August P, BrooksMM,Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ,­Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME,­NestoRW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes­and coronary artery disease. N Engl J Med 2009;360(24):2503–2515

335. Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA,­Pop-Busui R, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE. Impact­of left ventricular function and the extent of ischemia and scar by stress myocardial­perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients­with coronary artery disease: results from the Bypass Angioplasty Revascularization­Investigation 2 Diabetes (BARI 2D) trial. Journal of Nuclear Cardiology 2012;­19(4):658–669

336. Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ,­Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL. Clinical,­angiographic risk stratification differential impact on treatment outcomes in the­Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation­2012;126(17):2115–2124

337. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW,­Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM,­Investigators T-T. Greater clinical benefit of more intensive oral antiplatelet­therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement­in therapeutic outcomes by optimizing platelet inhibition with­prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118(16):­1626–1636

338. O’Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E,­Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA,­Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MS. An invasive or conservative­strategy in patients with diabetes mellitus and non-ST-segment elevation­acute coronary syndromes: a collaborative meta-analysis of randomized trials J Am Coll Cardiol 2012;60(2):106–111

339. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J,­Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable­angina and non-Q-wave myocardial infarction: results of the OASIS (Organization­to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;­102(9):1014–1019

340. Mehta SR, Granger CB, EikelboomJW, Bassand JP,Wallentin L, FaxonDP, Peters RJ,­Budaj A, Afzal R, Chrolavicius S, Fox KA, Yusuf S. Efficacy and safety of fondaparinux­vs. enoxaparin in patients with acute coronary syndromes undergoing percutaneous­coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol­2007;50(18):1742–1751

341. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J,­Husted S, James S, Katus H, MahaffeyKW, Scirica BM, Skene A, Steg PG, Storey RF,­Harrington RA, Freij A, Thorsen M. Ticagrelor vs. clopidogrel in patients with acute­coronary syndromes. N Engl J Med 2009;361(11):1045–1057

342. Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E,Wallentin L, Fast Revascularisation­during InStability in Coronary artery disease I. 5-year outcomes in the FRISC-II­randomised trial of an invasive vs. a non-invasive strategy in non-ST-elevation acute­coronary syndrome: a follow-up study. Lancet 2006;368(9540):998–1004

343. Damman P, Hirsch A, Windhausen F, Tijssen JG, de Winter RJ. 5-year clinical outcomes­in the ICTUS (Invasive vs. Conservative Treatment in Unstable coronary­Syndromes) trial a randomized comparison of an early invasive vs. selective invasive­management in patients with non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 2010;55(9):858–864

344. Abdallah MS,Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, Cohen DJ,­Investigators FT. Quality of life after PCI vs.CABG among patients with diabetes and­multivessel coronary artery disease: a randomized clinical trial. JAMA 2013;310(15):­1581–1590

345. SerruysPW, Farooq V. Revascularization strategies in patients with diabetes.NEngl­J Med 2013;368(15):1454–1455

346. Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW,­Dawkins KD, Mack MJ, Investigators S. Treatment of complex coronary artery­disease in patients with diabetes: 5-year results comparing outcomes of bypass­surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac­Surg 2013;43(5):1006–1013

347. Kapur A, Hall RJ, Malik IS, QureshiAC, Butts J, de Belder M, Baumbach A, Angelini G,­de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP,­Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention­with coronary artery bypass grafting in diabetic patients. 1-year results of the­CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol­2010;55(5):432–440

348. Kamalesh M, Sharp TG, Tang XC, Shunk K,Ward HB,Walsh J, King S 3rd, Colling C,­Moritz T, Stroupe K, Reda D. Percutaneous coronary intervention vs. coronary­bypass surgery in United States veterans with diabetes. J Am Coll Cardiol 2013;­61(8):808–816

349. Verma S, Farkouh ME, Yanagawa B, Fitchett DH, AhsanMR, Ruel M, Sud S, Gupta M,­Singh S, Gupta N, Cheema AN, Leiter LA, FedakPW, Teoh H, Latter DA, Fuster V,­Friedrich JO. Comparison of coronary artery bypass surgery and percutaneous­coronary interventions in patients with diabetes: a meta-analysis of randomised­controlled trials. Lancet Diabetes & Endocrinology 2013;1(4):317–328

350. Hakeem A, Garg N, Bhatti S, Rajpurohit N, Ahmed Z, Uretsky BF. Effectiveness of­percutaneous coronary intervention with drug-eluting stents compared with­bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic­reviewand meta-analysis of randomized clinical data. JAmHeart Assoc 2013;­2(4):e000354

351. Stettler C, Allemann S,Wandel S, Kastrati A, Morice MC, Schomig A, Pfisterer ME,­StoneGW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H,­Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M,­Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Juni P Drug eluting and bare metal stents in people with and without diabetes: collaborative­network meta-analysis. BMJ 2008;337:a1331

352. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO,­Slater J, Cutlip DE, Feit F. Outcomes with various drug eluting or bare metal stents in­patients with diabetes mellitus: mixed treatment comparison analysis of 22,844­patient years of follow-up from randomised trials. BMJ 2012;345:e5170

353. TaggartDP, Altman DG, Gray AM, Lees B, Nugara F, Yu LM, Campbell H, Flather M Randomized trial to compare bilateral vs. single internal mammary coronary artery­bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur­Heart J 2010;31(20):2470–2481

354. Puskas JD, Sadiq A, Vassiliades TA, Kilgo PD, Lattouf OM. Bilateral internal thoracic­artery grafting is associated with significantly improved long-term survival, even­among diabetic patients. Annals of Thoracic Surgery 2012;94(3):710–715;discussion­715–716

355. Locker C, Schaff HV, Dearani JA, Joyce LD, Park SJ, Burkhart HM, Suri RM,­Greason KL, Stulak JM, Li Z, Daly RC. Multiple arterial grafts improve late survival­of patients undergoing coronary artery bypass graft surgery: analysis of 8622­patients with multivessel disease. Circulation 2012;126(9):1023–1030

356. Schwann TA, Al-Shaar L, Engoren M, Habib RH. Late effects of radial artery vs.saphenous­vein grafting for multivessel coronary bypass surgery in diabetics: a­propensity-matched analysis. Eur J Cardiothorac Surg 2013;44(4):701–710

357. Giugliano RP, White JA, Bode C, Armstrong PW, Montalescot G, Lewis BS, van ’t­Hof A, Berdan LG, Lee KL, Strony JT, Hildemann S, Veltri E, Van de Werf F,­Braunwald E, Harrington RA, Califf RM, Newby LK, Investigators EA. Early vs delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med­2009;360(21):2176–2190

358. Mellbin LG, Malmberg K, Norhammar A,Wedel H, Ryden L. The impact of glucose­lowering treatment on long-term prognosis in patients with type 2 diabetes and­myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008;29(2):­166–176

359. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P,­Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G,­Bataille V, Cambou JP, Ferrieres J, Simon T. Impact of type of preadmission sulfonylureas­on mortality and cardiovascular outcomes in diabetic patients with acute­myocardial infarction. The Journal of Clinical Endocrinology and Metabolism 2010;­95(11):4993–5002

360. Takagi T, Okura H, Kobayashi Y, Kataoka T, Taguchi H, Toda I, Tamita K,­Yamamuro A, Sakanoue Y, Ito A, Yanagi S, Shimeno K, Waseda K, Yamasaki M,­Fitzgerald PJ, Ikeno F, Honda Y, Yoshiyama M, YoshikawaJ.Aprospective, multicenter,­randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression­in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal­Proliferation by Pioglitazone Study). JACC Cardiovascular Interventions 2009;2(6):­524–531

361. Bhamidipati CM, LaPar DJ, Stukenborg GJ, Morrison CC, Kern JA, Kron IL,­Ailawadi G. Superiority of moderate control of hyperglycemia to tight control in­patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg­2011;141(2):543–551

362. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P,­Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR,­Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular­outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):­1317–1326

363. Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL,Westerhout CM,­Simes RJ, Granger CB, Zijlstra F, Primary Coronary Angioplasty vs.Thrombolysis-2­Trialists Collaborators G. Primary percutaneous coronary intervention compared­with fibrinolysis for myocardial infarction in diabetes mellitus: results from the­Primary Coronary Angioplasty vs. Thrombolysis-2 trial. Arch Intern Med 2007;­167(13):1353–1359

364. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N,­Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM,­Braunwald E, Investigators TTiMI. Comparison of early invasive and conservative­strategies in patients with unstable coronary syndromes treated with the glycoprotein­IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879–1887

365. Roffi M, Topol EJ. Percutaneous coronary intervention in diabetic patients with­non-ST-segment elevation acute coronary syndromes. Eur Heart J 2004;25(3):­190–198

366. Lindahl B, Toss H, Siegbahn A, Venge P,Wallentin L. Markers of myocardial damage­and inflammation in relation to long-term mortality in unstable coronary artery­disease. FRISC Study Group. Fragmin during Instability in Coronary Artery­Disease. N Engl J Med 2000;343(16):1139–1147

367. Lima EG, Hueb W, Garcia RM, Pereira AC, Soares PR, Favarato D, Garzillo CL,­D’Oliveira Vieira R, Rezende PC, Takiuti M, Girardi P, Hueb AC, Ramires JA, Kalil­Filho R. Impact of diabetes on 10-year outcomes of patients with multivessel coronary­artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial Am Heart J 2013;166(2):250–257

368. Dorman MJ, Kurlansky PA, Traad EA, Galbut DL, Zucker M, Ebra G. Bilateral internal­mammary artery grafting enhances survival in diabetic patients: a 30-year followup­of propensity score-matched cohorts. Circulation 2012;126(25):2935–2942

369. Chertow GM, Normand SL, McNeil BJ. "Renalism": inappropriately low rates of­coronary angiography in elderly individuals with renal insufficiency. J Am Soc­Nephrol 2004;15(9):2462–2468

370. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive­cardiac procedures after acute myocardial infarction in long-term dialysis patients Am Heart J 2006;152(3):558–564

371. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U,­Wallentin L, Jernberg T. Influence of renal function on the effects of early revascularization­in non-ST-elevation myocardial infarction: data from the SwedishWeb-­System for Enhancement and Development of Evidence-Based Care in Heart­Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation­2009;120(10):851–858

372. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, GhaliWA Survival after coronary revascularization among patients with kidney disease. Circulation­2004;110(14):1890–1895

373. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS,­Califf RM, Mark DB, OwenWFJr. Chronic kidney disease, mortality, and treatment­strategies among patients with clinically significant coronary artery disease. JAmSoc­Nephrol 2003;14(9):2373–2380

374. Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, Rogers P, Kougias P,­Birnbaum Y, Paniagua D, Kar B, Ballantyne C, Bozkurt B, Jneid H. Patients with­severe chronic kidney disease benefit from early revascularization after acute coronary­syndrome. Int J Cardiol 2013;168(4):3741–3746

375. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, Anstrom KJ,­Eisenstein EL, Dokholyan RS, Peterson ED, Douglas PS. Safety and efficacy of­drug-eluting stents in older patients with chronic kidney disease: a report from­the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol 2011;58(18):­1859–1869

376. Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic­kidney disease: a prospective registry study. PLoS One 2010;5(11):e15070

377. Ashrith G, LeeVV, ElaydaMA, ReulRM, Wilson JM. Short- and long-term outcomes­of coronary artery bypass grafting or drug-eluting stent implantation for multivessel­coronary artery disease in patients with chronic kidney disease. Am J Cardiol 2010;­106(3):348–353

378. Charytan DM,Li S, Liu J, Herzog CA. Risks of death and end-stage renal disease after­surgical compared with percutaneous coronary revascularization in elderly­patients with chronic kidney disease. Circulation 2012;126(11 Suppl 1):S164–9

379. Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, LindeboomW, O’NeillWW,­WijnsW, SerruysPW. Association of chronic kidney disease with clinical outcomes­after coronary revascularization: the Arterial Revascularization Therapies Study­(ARTS). Am Heart J 2005;149(3):512–519

Не нашли, что искали? Воспользуйтесь поиском: